Cargando…
Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
BACKGROUND: Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. METHODS: We conducted a single-center retrosp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653473/ https://www.ncbi.nlm.nih.gov/pubmed/37972037 http://dx.doi.org/10.1371/journal.pone.0294490 |
_version_ | 1785147784339390464 |
---|---|
author | Shin, Hong-Joon Yoon, Joon-Young Na, Young-Ok Lee, Jae-Kyeong Kho, Bo Gun Kim, Tae-Ok Kim, Yu-Il Lim, Sung-Chul Jeong, Sae-Hee Kwon, Yong-Soo |
author_facet | Shin, Hong-Joon Yoon, Joon-Young Na, Young-Ok Lee, Jae-Kyeong Kho, Bo Gun Kim, Tae-Ok Kim, Yu-Il Lim, Sung-Chul Jeong, Sae-Hee Kwon, Yong-Soo |
author_sort | Shin, Hong-Joon |
collection | PubMed |
description | BACKGROUND: Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. METHODS: We conducted a single-center retrospective cohort study. From January 2010 through June 2017, we assessed all consecutive TB patients at Chonnam National University Hospital in South Korea. Hyperuricemia was defined as serum uric acid levels exceeding 7.0 mg/dL (men) and 6.0 mg/dL (women). RESULTS: Of the 1,143 patients included, PZA was administered to 1,081 (94.6%), and hyperuricemia was detected in 941 (82.3%). Eight patients experienced MACEs. Multivariate analysis using logistic regression indicated that prior ischemic heart disease was associated with MACE development (OR,14.087; 95% CI,3.304–60.061; P < 0.000), while hyperuricemia was not (OR, 1.505; 95% CI, 0.184–12.299; P = 0.703). For patients without drug-resistant TB, the absence of hyperuricemia was associated with higher mortality (OR, 2.609; 95% CI, 1.066–6.389; P = 0.036), whereas hyperuricemia was associated with less worse outcomes (OR,0.316; 95% CI,0.173–0.576; P < 0.000). CONCLUSIONS: Although most patients treated with PZA developed hyperuricemia, it was not associated with MACE development. Hyperuricemia during TB treatment was associated with better outcomes, possibly due to consistent adherence to TB treatment. |
format | Online Article Text |
id | pubmed-10653473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-106534732023-11-16 Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment Shin, Hong-Joon Yoon, Joon-Young Na, Young-Ok Lee, Jae-Kyeong Kho, Bo Gun Kim, Tae-Ok Kim, Yu-Il Lim, Sung-Chul Jeong, Sae-Hee Kwon, Yong-Soo PLoS One Research Article BACKGROUND: Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. METHODS: We conducted a single-center retrospective cohort study. From January 2010 through June 2017, we assessed all consecutive TB patients at Chonnam National University Hospital in South Korea. Hyperuricemia was defined as serum uric acid levels exceeding 7.0 mg/dL (men) and 6.0 mg/dL (women). RESULTS: Of the 1,143 patients included, PZA was administered to 1,081 (94.6%), and hyperuricemia was detected in 941 (82.3%). Eight patients experienced MACEs. Multivariate analysis using logistic regression indicated that prior ischemic heart disease was associated with MACE development (OR,14.087; 95% CI,3.304–60.061; P < 0.000), while hyperuricemia was not (OR, 1.505; 95% CI, 0.184–12.299; P = 0.703). For patients without drug-resistant TB, the absence of hyperuricemia was associated with higher mortality (OR, 2.609; 95% CI, 1.066–6.389; P = 0.036), whereas hyperuricemia was associated with less worse outcomes (OR,0.316; 95% CI,0.173–0.576; P < 0.000). CONCLUSIONS: Although most patients treated with PZA developed hyperuricemia, it was not associated with MACE development. Hyperuricemia during TB treatment was associated with better outcomes, possibly due to consistent adherence to TB treatment. Public Library of Science 2023-11-16 /pmc/articles/PMC10653473/ /pubmed/37972037 http://dx.doi.org/10.1371/journal.pone.0294490 Text en © 2023 Shin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Shin, Hong-Joon Yoon, Joon-Young Na, Young-Ok Lee, Jae-Kyeong Kho, Bo Gun Kim, Tae-Ok Kim, Yu-Il Lim, Sung-Chul Jeong, Sae-Hee Kwon, Yong-Soo Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
title | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
title_full | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
title_fullStr | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
title_full_unstemmed | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
title_short | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
title_sort | major adverse cardiovascular events and hyperuricemia during tuberculosis treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653473/ https://www.ncbi.nlm.nih.gov/pubmed/37972037 http://dx.doi.org/10.1371/journal.pone.0294490 |
work_keys_str_mv | AT shinhongjoon majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT yoonjoonyoung majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT nayoungok majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT leejaekyeong majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT khobogun majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT kimtaeok majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT kimyuil majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT limsungchul majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT jeongsaehee majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment AT kwonyongsoo majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment |